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Robotic surgery for gynecologic cancers: indications, 
techniques and controversies
Kiran H. Clair, Krishnansu S. Tewari
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of 
California, Irvine, Orange, California, USA
Abstract
Minimally invasive surgery for gynecologic cancers is associated with fewer postoperative 
complications including less blood loss and quicker recovery time compared to traditional 
laparotomy. The robotic platform has allowed patients access to minimally invasive surgery due to 
its increased utilization by gynecologic oncologists. Many surgeons have embraced the robotic 
platform due to its technological advances over traditional laparoscopy including high-definition 
3D optics, wristed instrumentation, camera stability and improved ergonomics. While robotic 
surgery continues as a mainstay in the management of gynecologic cancers, it remains 
controversial in regards to its cost effectiveness and more recently, its long-term impact on clinical 
and oncologic outcomes. A strong component of the justification of this surgical platform is based 
on extrapolated data from traditional laparoscopy despite limited prospective randomized trials for 
robotic-assisted surgery. In this review, we highlight the use of robotic surgery in the management 
of gynecologic cancers in special populations: fertility sparing patients, the morbidly obese, the 
elderly, and patients with a favorable response to neoadjuvant chemotherapy.
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Historical Notes
It is best estimated that Leonardo da Vinci (1452–1519) first sketched his prototype for a 
robotic mechanical knight over five centuries ago. While many centuries later, the namesake 
surgical platform has transformed the field of minimally invasive surgery. Da Vinci’s robotic 
knight consisted of a complex core of mechanical devices that is thought to be human 
powered. The two operating systems of the robot included those with 3° of freedom (legs, 
ankles, knees and hips) and those with 4° of freedom (shoulder, elbows, wrists and hands).1 
Da Vinci’s mechanical designs were far ahead of the development of any formal design 
prints. Similarly, da Vinci’s contribution to anatomy and anatomic illustration were far ahead 
of the contemporary scientific work that would occur almost two centuries later.2 (Fig. 1) 
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The namesake robotic platform thus captures the essence of Da Vinci’s work including the 
novel pursuit of mechanical and robotic design in addition to his pursuit of anatomic 
knowledge. (Fig. 2)
While the concept of robotic design may have been first introduced by Leonardo da Vinci, 
the field of ’telesurgery’ or the ability to operate at a remote site with the use of robotic 
technology is an emerging area of interest.3 The ability to offer complex minimally invasive 
surgery at a site remote from the patient offers the potential to bring a more advanced level 
of care in remote areas, potentially saving lives around the world. Not only can this type of 
technology help in humanitarian situations with limited access, the military has also pursued 
this type of technology to assist in emergency areas.4 This type of ťelecommunication’ and 
ťelesurgery’ can be applied in a wide variety of clinical scenarios allowing patients access to 
a skilled surgeon remotely. Ongoing research is being conducted to better understand the 
amount ot distance possible for remote telesurgery to be feasible.5,6
The da Vinci Surgical System (Intuitive Surgical Inc.) was first introduced in 2000 as the 
first robotic surgical system approved by the US Food and Drug Administration (FDA). The 
surgical platform was eventually approved for use in gynecologic malignancies in 2005. It is 
estimated that more than 6 million surgeries have been performed globally using the surgical 
platform (www.davincisurgery.com). Since its initial approval, the utilization of the Da Vinci 
robotic platform has rapidly increased in the field of gynecologic oncology. While much of 
the debate surrounding the adoption of robotic surgery has focused on the cost effectiveness 
and the immediate postsurgical outcomes., the benefits of improved ergonomics and 
advanced instrumentation are important considerations in surgeon preference (Table 1). 
There are few large randomized control trials that investigate the potential discrepancy 
between laparoscopic and robotic surgery and also robotic versus open surgery. More 
recently, long-term safety concerns regarding oncologic outcomes associated with minimally 
invasive surgery (laparoscopy and robotic-assistance) in the management of early cervical 
cancer has led the US FDA to issue a ‘safety communication’. In February 28, 2019, the US 
FDA cited ‘limited, preliminary evidence’ that the use of robotically assisted surgical 
devices for the treatment or prevention of cancers (e.g., breast and cervical) may be 
associated with diminished long term-survival. The FDA acknowledged that while 
robotically assisted devices allow for quicker recovery and improved surgical technique, 
limited studies have been performed to evaluate the specific oncologic clinical outcomes 
such as local cancer recurrence, disease free interval, or overall survival.7
Current Indications
Cervical cancer
Despite increased access to cervical cancer screening and implementation of human 
papillomavirus (HPV) vaccination programs, in 2018 there were approximately 569 847 
cases of cervical cancer diagnosed worldwide.8 In the United States, in 2020 there are an 
estimated 13,800 new cases and 4,290 disease related deaths.9 For decades, abdominal 
radical hysterectomy had been the standard of care for the surgical management of early 
FIGO stage cervical cancer with 5-year overall survival rates greater than 80%.10 According 
to the National Comprehensive Cancer Network (NCCN) guidelines, radical hysterectomy 
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remains the standard surgical treatment for early FIGO stage cervical cancer.11 Unlike an 
extrafacial hysterectomy, a radical hysterectomy is a complex surgery to perform and teach. 
It requires development of the pararectal, paravesical, vesicouterine, and rectovaginal spaces, 
ligation of the uterine arteries at their origin along the internal iliac arteries, bilateral 
ureterolysis from the pelvic brim to bladder insertion, resection of the cardinal ligaments at 
the pelvic sidewall, resection of the uterosacral ligaments at the pelvic floor (sacrum), and 
removal of one quarter to one third of the proximal vagina. (3). Bilateral pelvic 
lymphadenectomy is also routinely performed as part of a radical hysterectomy.
Historically, either an open or minimally invasive (laparoscopic or robotic) surgical approach 
was acceptable for radical hysterectomy (4). The first robotic-assisted radical hysterectomy 
was reported in 2005 and prompted the beginning of a national trend toward increasing 
usage of the robotic platform. Between 2008 and 2015, 3563 radical hysterectomies were 
performed based on the National Inpatient Sample (NIS) data, of which 27.5% were 
performed using a minimally invasive approach (robotic and laparoscopic).13 Prior studies 
have demonstrated that compared to an open approach, minimally invasive (laparoscopic or 
robotic) techniques are associated with decreased blood loss, fewer complications, and a 
shorter hospital stay.13–16 Additional retrospective studies demonstrated no differences 
between robotic-assisted radical hysterectomy and open surgery in regards to recurrence 
rates or death (Table 2).12,16
Following the publication of the Laparoscopic Approach to Cervical Cancer (LACC trial; 
Clinicaltrials.gov NCT00614211) in October 2018, the safety of a minimally invasive 
approach to radical hysterectomy for early cervical cancer was significantly challenged. 
Ramirez et al. published a prospective, randomized trial involving stages IA1 
(lymphovascular invasion), IA2, or IB1; with patients who underwent a minimally invasive 
approach having a lower rate of disease-free survival at 4.5 years, 86.0% (MIS) compared to 
96.5% for open surgery (difference of −10.6 percentage points; 95% CI −16.44.7; p=0.87 for 
non-inferiority).17 Of the minimally invasive surgical patients, approximately 84.4% 
underwent laparoscopy and 15.6% robot-assisted surgery. The study was prematurely closed 
due to an imbalance in deaths between the groups, with differences in overall survival rates 
at 3 years 93.8% (MIS) and 99.0% (open). As a companion piece published alongside the 
LACC trial, Melamed et al. analyzed the National Cancer Database and Surveillance, 
Epidemiology and End Results (SEER) database, demonstrating a decline in relative 
survival, with patients who underwent minimally invasive surgery having a worse 4-year 
mortality rate of 9.1% compared to 5.3% among those who underwent open surgery. In 
subgroup analysis, however, the hazard ratio for death for patients with tumors <2 cm were 
statistically similar.18 There remains significant concerns regarding the inherent flaws of a 
database study with the biases associated with retrospective analyses. Similarly, Doo et al. 
retrospectively evaluated patients with stage IB1 cervical cancer and found no difference in 
perioperative complications; however, on multivariate analysis found that robotic radical 
hysterectomy or tumor size ≥2 cm (irrespective of surgical approach), were independently 
associated with recurrence and death.19
The LACC study highlights several challenges when designing surgical randomized trials 
including limited selection criteria of participating surgeons regarding volume and baseline 
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outcomes, as well as the standardization of surgical technique, including learning curves. 
Radical hysterectomy at baseline is a complex surgery to learn and to teach, however, trying 
to perform this surgery using a minimally invasive approach such as laparoscopy can also 
lead to significant variation in technique and skill. The LACC trial was performed across 33 
centers in 13 countries over a 9-year period. In order for a surgeon to be considered for the 
trial, they were required to have a minimum of 10 documented cases as the primary surgeon, 
a proven track record with clinical research and hospital privileges and to have submitted 1 
unedited surgical video. While there has been significant research showing improved 
outcomes with decreased recurrence risk and improved survival in high-volume centers, 
surgical volume was not a component in surgeon selection.20 Additionally, the majority of 
centers participating in the study were outside of the United States (27/33 centers), where 
there is limited oversight and regulation of surgical training compared to the rigor of US-
based Gynecologic Oncology training programs.
An additional challenge included the standardization of surgical technique to improve study 
uniformity. In the LACC trial, unlike other surgical trials, there was no standardization or 
documentation required by the participating center to assess the performance of appropriate 
surgical technique during the study period. For patients randomized to the minimally 
invasive arm, it was up to the surgeon to decide between a laparoscopic vs robotic approach, 
with 16% of patients undergoing robotic-assisted radical hysterectomy (RRH). Concern for a 
lack of uniformity in surgical technique is also supported by the inconsistent finding of 
similar postoperative complication rates between the MIS and open radical hysterectomy 
groups (25 vs 26%). The similar rates between the two groups is contradictory to many 
studies that have demonstrated less blood loss, decreased operative time, fewer blood 
transfusions and shorter length of stay with MIS (Table 2). Additionally, key elements in 
robotic-assisted surgery that may make this approach more similar to open surgery 
compared to laparoscopy, including improved visualization and depth perception with 3D 
technology, efficiency in suturing, and more precise dissections were not accounted for 
during the study period in either surgeon reported outcomes or pathologic specimen 
analysis. While the landmark LACC trial is the highest level of evidence published to date, 
currently MIS may still be an acceptable option in select cases. Only 16% of patients 
underwent RRH and therefore the extrapolation of data is difficult to interpret. Additional 
information is needed to better understand why a minimally invasive approach may be 
resulting in worse survival for early stage cervical cancer patients undergoing radical 
hysterectomy.
Intrauterine manipulator
Following the landmark LACC trial, significant attention has been directed to the specific 
surgical techniques used in minimally invasive surgery that could be contributing to the 
overall survival differences which includes the use of the intrauterine manipulator. Unlike 
open surgery, upward traction on the uterus with the use of an intrauterine manipulator is a 
critical step in allowing adequate exposure to safely perform the procedure. Although it has 
been hypothesized that the introduction of a uterine manipulator may disrupt tumor and 
cause dissemination of cancer cells, this has been refuted by several studies that have failed 
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to show a difference in the risk of recurrence or overall survival in the management of 
endometrial cancer.21–24
The use of the manipulator for cervical cancer remains slightly more controversial. 
Rakowski et al. retrospectively evaluated clinical-data and tumor pathology from open and 
robotic-assisted radical hysterectomy cases and found no difference in depth of invasion, 
lymphovascular space invasion, or parametrial involvement.25 There are only case reports of 
artefactual displacement of CIN III to fallopian tubes during laparoscopic hysterectomy with 
use of the intrauterine manipulator; however, this raises a theoretical mechanism of cervical 
cancer cell dissemination into the peritoneal cavity.26
Special populations
Tumors ≤ 2 cm—A major limitation of the LACC trial was the inability to generalize the 
results of the trial to ‘low risk’ cervical cancer cases including tumors of less than 2 cm due 
to the trial being under-powered.17 Additionally, in the companion retrospective SEER 
database study, there was no survival difference observed between the two surgical methods 
for patients with a tumor of less than 2 cm.18 The significance of the 2 cm size cut-off has 
also been incorporated in the most updated FIGO cervical cancer staging, suggesting that 
this tumor size is of oncologic significance.27 Therefore, given the limited data in patients 
with small lesions or < 2 cm, among appropriately selected cases, robotically assisted 
surgery may still be an appropriate option after thorough counseling.28,29
Fertility sparing—While the standard treatment for early-stage cervical cancer remains 
radical hysterectomy with pelvic lymphadenectomy, in patients who desire future fertility, 
the option of radical trachelectomy with pelvic lymphadenectomy may be considered. 
Several prognostic factors have been identified including histology, LVSI, and deep stromal 
invasion when comparing radical trachelectomy to radical hysterectomy for management.30 
Tumor size remains controversial with several studies demonstrating conflicting results 
regarding outcomes for tumors greater or less than 2 cm.31,32 There remains limited data 
regarding the role and outcomes of robotically assisted trachelectomy for cervical cancer. 
Currently, a multinational study (IRTA study) assessing differences between an open vs 
minimally invasive (robotic or laparoscopic) approach to radical trachelectomy is underway 
and will help inform clinical practice.
Endometrial cancer
In 2019, there will be an estimated 65,620 new cases of endometrial cancer diagnosed and 
12,590 deaths attributed to the disease in the United States.9 The current treatment for early-
stage endometrial cancer includes an extrafascial hysterectomy, bilateral salpingo-
oophorectomy with or without a pelvic lymphadenectomy or aortic lymph node sampling. 
Unlike cervical cancer, there are several landmark randomized controlled trials that have 
evaluated the safety and feasibility of minimally invasive surgery in the management of 
endometrial cancer. The Gynecologic Oncology Group LAP2 Study (GOG-LAP2; 
Clinicaltrials.gov NCT00002706) was the first trial that demonstrated improved short-term 
surgical outcomes including shorter hospital stay and fewer complications with laparoscopy 
compared to open surgery.33 Notably, the conversion rate from laparoscopy to open surgery 
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was 26%. The study evaluated more than 2500 patients, and reported no difference in overall 
survival or recurrence between the two arms.34 Additional studies include the Laparoscopic 
Approach to Cancer of the Endometrium (LACE; Clinicaltrails.gov NCT00096408) trial, a 
multinational, randomized trial evaluating laparoscopic vs open hysterectomy, which again 
showed no difference in disease-free survival or overall survival at 4.5 years.35
To date, there are no large randomized trials comparing laparoscopy, laparotomy and 
robotic-assisted surgery in the management of endometrial cancers. A systematic review 
published in 2010 compared all three surgical modalities (laparoscopy, laparotomy and 
robotic assistance) and analyzed eight studies which included 1591 patients. Robotic surgery 
was associated with less blood loss compared to both laparoscopy and laparotomy, operative 
times were longer with robotic and laparoscopy (however both were similar) than 
laparotomy, and length of stay was shorter for minimally invasive approaches. The 
conversion rates for laparotomy were 4.0% for robotic-assisted and 9.9% for laparoscopy; 
however, this difference was not statistically significant.36 Ran et al. also conducted a meta-
analysis in 2014, which included 22 studies that compared the three surgical approaches and 
similarly concluded that robotic surgery is safe and may be beneficial over traditional 
laparoscopy. They found similar operative times between laparoscopy and robotic 
approaches however demonstrated less blood loss and lower conversion rates in robotic 
cases.37 In 2019, a Danish study prospectively reviewing outcomes of early-stage 
endometrial cancer cases found that abdominal hysterectomy was associated with increased 
odds of severe complications compared to a minimally invasive approach (OR, 2.58; 95% CI 
1.80–3.70) and was associated with higher mortality compared to laparoscopic and robotic 
approaches (laparoscopic HR 1.42; 95%CI 1.02–1.97 and HR 1.70; 95%CI 1.31–2.19, 
respectively).38
At this time, the evidence continues to support the use of minimally invasive surgery over 
laparotomy in the management of early stage endometrial cancer. Several studies have also 
suggested a benefit in robotic assistance over laparoscopy, which has been associated with 
decreased blood loss and lower conversion rates to open surgery. Additional randomized 
studies are needed to assess the long-term oncologic outcomes.
Surgical techniques
At our institution, patients are counseled prior to surgery regarding postoperative care 
including the option for same-day discharge, which is routinely offered with the exception of 
patients with significant medical co-morbidities. Prior to surgery, we use a ‘T-Score’ system 
to stratify patients based on several factors: BMI (body mass index), uterine size, history of 
abdominal surgeries, vaginal parity and cardiopulmonary reserve (Table 3). This scoring 
system allows for appropriate pre-operative counseling on the success of a robotic-assisted 
approach. Mechanical bowel prep or antibiotics are not routinely administered prior to 
surgery; however, if a para-aortic lymphadenectomy is highly anticipated, Miralax with two 
bisacodyl tablets are prescribed to improve visibility. We routinely use a TrenGuard 450 
Trendelenburg restraint, which aims to eliminate patients sliding in Trendelenburg position 
by placing stabilizing pillows to effectively act as a ‘speed bump’. This technology can 
secure patients up to 450 pounds in up to 40° of Trendelburg. In positioning obese patients, 
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we recommend a stepwise approach by testing ventilator pressures by incrementally placing 
the patient in steep Trendelenburg. For high-risk patients, we also recommend placement of 
two peripheral intravenous cannulae prior to tucking arms to improve access in the event of 
major bleeding in addition to having a laparotomy tray available in the room. In our 
experience, uterine manipulation is helpful to improve visibility and safety. We routinely use 
the V-Care disposable uterine manipulator (ConMed).
For abdominal entry, we anesthetize port sites with 0.5% bupivacaine, and prefer direct entry 
method with an 8 mm optical trocar under direct visualization prior to CO2 insufflation. The 
four DaVinci robotic ports are 8 mm in size but we recommmend making a 9 mm incision at 
each entry site in order to facilitate smooth placement (without excessive pressure due to 
skin dystocia) of each cannula using the clear plastic tapered obturator for Xi arms 1, 2, and 
4. The placement of the camera port depends on the patienťs body habitus, uterine size, and 
the need for para-aortic lymphadenectomy; this port is generally placed 23–27 cm superior 
to the pubic symphysis. A zerodegree camera lens is placed in the third arm of the Xi, 
monopolar scissors are placed in the fourth arm, a bipolar fenestrated grasper is placed in the 
second arm, and a double fenestrated pro-grasp is placed in the first arm. The robot is side-
docked on the left side of the patient. (Fig. 3) After delivery of the uterus through the vagina, 
a sterile lap is placed within a glove to occlude the vagina during cuff closure. The 
monopolar and bipolar instruments are exchanged for a DaVinci Mega Suturecut Needle 
Driver and DaVinci Mega Needle Driver, respectively. 0 vicryl ct-1 sutures x 2 are then 
introduced via the assistant port and vaginal cuff closure is accomplished with surgeon’s 
knots at each angle and then a running locking stitch towards the center of the cuff where the 
sutures are tied together and the needles removed and retrieved through the assistant port. 
Following the running of one side of the cuff, the double fenestrated pro-grasp can be used 
to maintain upward traction on the cuff and tension on the repair while the surgeon begins 
the closure on the opposite side.
The placement of the five ports follows a gentle ‘rainbow’ pattern on the abdomen with the 
assistant port in the right lower quadrant, directly opposite the DaVinci Xi arm 1 in the left 
lower quadrant. When pelvic lymphadenectomy is anticipated, we use a 12 mm AirSeal 
System Insufflation (ConMed) and have the console surgeon use the robot to assist the 
surgical assistant in closing the 12 mm port with 0 vicryl suture delivered with the Carter 
Thomason Fascial Closure Device to prevent hernia formation. When lymphadenectomy is 
not planned, we use a 5 mm assisant port and pass 0 vicryl ct-2 sutures x 2 through the Xi 
arm 1 port for vaginal cuff closure. Once both sutures have been delivered, the surgeon can 
place one needle into the undersurface of the anterior abdominal wall for security and the 
surgical assistant replaces the double fenestrated pro-grasp in the Xi arm 1 to facilitate 
vaginal cuff closure. The needles are then returned through the Xi arm 1. Finally, for women 
with large uteri (12–14 cm or greater) that cannot be delivered transvaginally, a small mini-
laparotomy incision in the direction of Pfannensteil can be performed with the robot 
remaining docked; the uterus is delivered through the incision which is then quickly repaired 
and the console surgeon then proceeds to close the vaginal cuff robotically.
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Sentinel lymphadenectomy and firefly fluorescence
The sentinel lymph node (SLN) algorithm was first incorporated into the NCCN guidelines 
for patients with endometrial cancer in 2014.39 Since 2011, there has been a rapid increase 
in the use of SLN to detect nodal metastasis, with the most notable increase observed in 
women undergoing robotic-assisted hysterectomy.40 The FIRES trial (Clinicaltrials.gov 
NCT01673022) is a multicenter, prospective, cohort study with 385 patients enrolled of 
which 340 underwent sentinel lymph node mapping using indocyanine green (ICG) and 
fluorescence imaging with complete pelvic lymphadenectomy. Of these patients, 41 (12%) 
patients had positive notes, of whom 36 had at least one mapped sentinel lymph node. Nodal 
metastases were identified in 97% (35/ 36) of the sentinel lymph nodes resulting in a 
sensitivity of 97.2% and a negative predictive value of 99.6%.41 Several studies have also 
compared the SLN detection rate with ICG compared to blue dye and found a superior 
detection rate with ICG (detection rate ICG 90.9% vs blue dye 64.4%, p< 0.0001).42,43
At our institution, for low-risk patients defined as endometrioid adenocarcinoma with <50% 
myometrial invasion, we have historically used intraoperative frozen section with Mayo 
criteria to triage patients for lymphadenectomy. Patients without myometrial invasion, grade 
1 or 2, or with a tumor size ≤2 cm are omitted from undergoing routine lymphadenectomy. 
Compared to the Mayo Clinic historical algorithm, the Memorial Sloan Kettering (MSK) 
surgical algorithm incorporated SLN mapping in all endometrial cancer staging in addition 
to the removal of any suspicious nodes. If there was no mapping on a hemi-pelvis, a side-
specific lymphadenectomy was performed with para-aortic lymphadenectomy at the 
surgeon’s discretion. In combination with the MSK algorithm, patients who undergo 
unsuccessful mapping of a hemi-pelvis, application of these criteria have been used 
selectively to omit them from undergoing lymphadenectomy by Mayo criteria. When 
reviewed retrospectively, Leiteo et al. found an increased proportion of patients undergoing 
pelvic lymph node excision with the SLN algorithm versus the selective Mayo LND 
algorithm, however fewer lymph nodes were removed with the SLN protocol. Overall, both 
approaches were without any compromise on short-term oncologic outcomes with similar 3-
year overall survival.44
We use a sentinel lymph node mapping protocol similar to the procedure presented in the 
FIRES trial. After induction of anesthesia, a standardized dose of 0.5 mg/mL of ICG tracer 
is injected into the cervix. This concentration is achieved by creating a dilution of 1 mL of 
the ICG solution (2.5 mg/mL) into 4 mL of sterile water. Using a 22-G spinal needle, 1 cc of 
the ICG solution is then injected into the cervix at 3 and 9 o’clock of the ectocervix 
approximately 1 cm deep, and an additional 1cc is injectedsuperficially at both sites. 
Following entry into the peritoneal cavity using the da Vinci Xi surgical robot, the ICG 
tracer can be used to visualize the lymphatic channels. Firefly fluorescence imaging for da 
Vinci Surgical System contains an 806 nm laser light source that allows ICG to fluoresce 
when illuminated. The fluorescent light is then captured with a special camera device that 
allows the ICG to be displayed in the visible light spectrum.45 Mapping is considered 
successful after observing a channel from the cervix leading to at least one lymph node in 
the hemi-pelvis. Following sentinel lymph node removal, specimens are routinely processed 
using the ultra-staging protocol. Sentinel lymph nodes are cut at 3 mm intervals; both 
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hematoxylin and eosin (H&E) and pancytokeratin immunohistochemistry staining are 
performed. Metastatic disease is defined as either macro- with greater than 2 mm of disease, 
micro- with 0.2–2 mm of disease volume, or isolated tumor cells with foci less than 2 mm in 
greatest dimension.
Para-aortic lymphadenectomy
While lymph node status is required for the complete FIGO surgical staging of endometrial 
cancer, the routine systematic use of para-aortic lymphadenectomy remains controversial.39 
Similar to what has been previously described, we use a center docked trans-peritoneal 
approach for para-aortic lymphadenectomy.46–48 The omentum and small bowel are 
carefully moved into the left upper quadrant using a Ray-Tec sponge to allow for adequate 
visualization. The procedure then starts with an incision of the peritoneum along the right 
common iliac artery medial to the ureter. This allows mobilization of the cecum cephaled. 
The bedside assistant then laterally retracts the ureter and ovarian vessels. Once the 
peritoneum is opened, the psoas muscle and genitofemoral nerve are identified. The 
dissection is extended to the bifurcation of the aorta allowing for removal of the common 
iliac lymph nodes with development of pedicles using monopolar cautery. The bedside 
assistant gently grasps the small bowel peritoneum then to adequately expose the duodenum 
and aorta to allow the dissection to continue along the entire surface of the inferior vena cava 
to the level of the reflection of the duodenum. The first arm is then used to retract the 
duodenum above the renal vein allowing for exposure. The lymph nodes are then dissected 
from the left renal vein to the inferior mesenteric artery (IMA) with blunt dissection and 
monopolar cautery, with care to avoid perforating lumbar vessels. Dissecting below the IMA 
down to the external iliac then completes the lymphadenectomy. We recommend that all 
major lymphatic trunks be bipolar cauterized or clipped to minimize the development of 
lymphoceles. The left ureter can be identifed by making a small window in the mesentery of 
the sigmoid colon.
Special populations
Obese patients—Surgery remains the primary treatment for endometrial cancer, and the 
approach used has a significant impact on the morbidity and cost associated with the 
management of obese patients. Obesity is a wellestablished risk factor for the development 
of endometrial cancer.49 In obese patients, similar benefits have been demonstrated with 
minimally invasive surgery.50 When evaluating the role of robotic surgery, several 
retrospective studies have shown findings consistent with prior studies evaluating 
laparoscopy.51–53 In 2008, Gehrig et al. retrospectively reviewed outcomes for obese and 
morbidly obese patients undergoing laparoscopy versus robotic-assisted surgery and found 
that robotic surgery was associated with shorter operative time (P = 0.0004), less blood loss 
(P < 0.0001), increased lymph node retrieval (P = 0.004) and shorter hospital stay (P = 
0.01199).52 When evaluating robotic surgery in super-morbidly obese patients (BMI ≥ 50 
kg/m2), a retrospective analysis of 168 patients found similar outcomes between 
supermorbidly obese patients compared to those with a lower BMI (length of stay, blood 
loss, complications, number of lymph nodes), suggesting that robotic surgery is a feasible 
option for these patients.54 While robotic surgery in the obese patient with endometrial 
cancer is safe and feasible, there is still limited prospective data evaluating the long-term 
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oncologic outcomes as well as cost effectiveness. For example while, Chan et al. 
demonstrated similar outcomes between laparoscopy and robotic-assisted surgical 
management in regards to intraoperative and postoperative complications, this study went 
further in highlighting the increased charges incurred with robotic surgery versus 
laparoscopy.55 For morbidly obese women, we use a step-wise approach of gradiated 
placement into steep Trendelenburg position (5 degrees at a time) allowing the patient to 
equilibrate as the anesthesiologist monitors tidal volumes and peak pressures. With this 
technique we have successfully provided minimally invasive robotic surgery to women with 
BMI 60–82.
Elderly—As life expectancy continues to increase in industrialized nations, we anticipate 
increasing rates of gynecologic malignancies diagnosed during later decades in life. This 
will likely present more challenging medical and surgical clinical scenarios. Surgery is often 
avoided altogether in some high-risk scenarios leading to significant undertreatment. 
Although most studies in these populations are retrospective, similar outcomes have been 
observed with decreased morbidity associated with laparoscopic surgery.56,57 In a 
retrospective analysis of patients from the Gynecologic Oncology Group LAP2 trial 
randomizing patients to laparotomy vs laparoscopy, patients greater than 60 years old 
experienced significantly less morbidity in the laparoscopic group. Patients across all ages 
experienced shorter hospital stay in the laparoscopy group, however, when stratifying by 
age, patients ≥60 years old with laparotomy had higher rates of antibiotic administration (P 
< 0.001), ileus (P < 0.001), pneumonias (P = 0.48), deep vein thrombosis (P = 0.035) and 
arrhythmias (P = 0.01) compared to laparoscopy.58 Leiteo et al. retrospectively evaluated 
982 patients who underwent robotic surgery for gynecologic cancer which were stratified by 
three age groups: 65–74, 75–84, and ≥ 85 years old. In multivariate analysis, ≥85 years was 
independently associated with 90-day mortality (4%), however, overall mortality rate 
remained low (0.5%) in the study.59 While much of the data applied to the aging population 
is extrapolated from laparoscopic surgery, a similar benefit may be conferred by robotic 
surgery; however, randomized data are limited.
Ovarian cancer
Despite being an effective form of treatment for endometrial cancer, there are few studies 
evaluating the role of robotic-assisted surgery in the initial staging or management of 
recurrent ovarian cancer. Currently, 15–25% of patients with ovarian cancer will be 
diagnosed at an early stage in the United States, thus complete surgical staging is a critical 
component of prognosis and treatment planning. According to NCCN guidelines, complete 
surgical staging should include hysterectomy, bilateral salpingooophorectomy, 
omentectomy, pelvic and para-aortic lymphadenectomy and peritoneal biopsies.60 Given the 
multiquadrant disease distribution, it has been argued that it is insufficient to assess disease 
in anatomically challenging locations (lesser sac, Morison’s pouch, mesentery) with MIS, 
arguing in favor of open surgery for intra-abdominal evaluation. Given the risk of tumor 
spillage and multiquadrant disease, robotic-assisted surgery or MIS is not recommended for 
the management of early or advanced stage ovarian cancer.61
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Neoadjuvant chemotherapy—There remains a lack of consensus on the superiority of 
neoadjuvant chemotherapy followed by interval cytoreductive surgery in the primary 
management of ovarian cancer.62–65 The results of the Japan Clinical Oncology Group 
JCOG 0602 and the SCORPION trial (Clinicaltrials.gov NCT01461850) are pending in 
addition to several ongoing studies (the Trial on Radical Upfront Surgery in Advanced 
Ovarian Cancer [TRUST] trial; Clinicaltrials.gov NCT02828618 and Study of Upfront 
Surgery Versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer 
(SUNNY) trial; Clinicaltrials.gov NCT02859038).62,63 Current NCCN guidelines 
recommend that neoadjuvant chemotherapy be considered for patients with bulky stage III or 
IV disease following an assessment by a gynecologic oncologist.60 Patients often respond to 
neoadjuvant chemotherapy and can have a complete response with absent gross residual 
disease prior to surgery. In this clinical context, the decision to perform robotic surgery 
requires extensive patient counseling and at minimum the following criteria: a normal 
CA-125, post-chemotherapy imaging scan without any evidence of disease (including an 
absence of ascites), a normal pelvic exam under anesthesia, and laparoscopic evaluation 
confirming an absence of visible disease or ascites.
Discussion
Robotic-assisted surgery has transformed the field of gynecologic oncology over the last 15 
years. This minimally invasive surgical platform has allowed an increasing number of 
patients access to the immediate benefits of MIS, including less blood less, shorter hospital 
stays, decreased wound complications, and quicker recovery time. Telesurgery and the 
ability for surgeons to operate remotely with robotic technology is emerging as an area of 
research. Recently, a robotic-assisted percutaneous coronary intervention was successfully 
performed at a site 10 miles away in Ahmedabad, India.6 While the field continues to move 
forward with more applications, it remains critical in the field of oncology that we continue 
to assess the oncologic safety. While many studies during the initial uptake of minimally 
invasive techniques consistently demonstrated the improved short-term outcomes for 
patients with less morbidity, additional studies including the LACC trial have challenged the 
MIS approach citing worse oncologic outcomes. While the FDA has issued a safety warning 
in regards to the robotic platform, a very small percentage of women underwent robotic 
surgery in the LACC trial. These limitations should be strongly considered when designing 
future randomized surgical trials. Additional randomized clinical trials are needed to better 
guide gynecologic oncologists in deciding the most appropriate surgical approach to 
optimize patient outcomes and appropriately triage patients.
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Self-portrait of Leonardo da Vinci (1452–1519) and his detailed sketch of female anatomy.
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Construction of Leonardo da Vinci’s mechanical drummer and mechanical knight, on 
display in Berlin. Designed around 1495 for a pageant in Milan, the Robotic Knight 
consisted of a life-size suite of armor filled with gears and wheels connected to an elaborate 
pulley and cable system allowing for independent motion (sitting down, standing up, moving 
its head, lifting its visor, and even playing the drums; rumors also suggested the Knight had 
the secret ability to write messages and draw pictures). This prototype was built by roboticist 
Mark Rosheim in 2002.
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The DaVinci Xi Surgical Robot and DaVinci Robot Firefly™ technology demonstrating 
sentinel lymphatic mapping for endometrial cancer through which near-infrared light excites 
indocyanine green tracer to emit a fluorescent signal. Images from Dr. Tewari’s surgical 
practice.
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Table 1
Advantages of Minimally Invasive Surgery (MIS, laparoscopic and robotic) compared to Laparotomy; 
Advantages of Laparoscopy compared to Robotics.
MIS Laparotomy
• Hospitalization not required (decreased hospital costs, 
reduced likelihood of contracting hospital-acquired infection)
• Tactile feedback
• Ability to remove large organs intact
• Shorter operating times (reduced OR costs, less exposure to
• Improved cosmesis and reduced risk of cellulitis, superficial 
wound separation, need for Wound VAC, hernia formation 
requiring mesh, diasthesis, evisceration with acidosis, intra-
abdominal adhesions with associated discomfort, hazardous 
subsequent surgery, and small bowel obstruction
• Less time to reach postoperative milestones (voiding, 
ambulation, regular diet, bowel function, pain control, 
driving, exercise, return
to work)
• Visualization magnified (less blood loss, fewer blood 
transfusions, fewer complications)
inhalational anesthetics, more efficient use of surgeon’s time)
• Expeditious control of catastrophic hemorrhage
• More complex operations possible
Laparoscopic Robotic
• Haptic feedback • Ergonomically superior
• Cost-effective • Intuitive nature
• Fewer and smaller incisions • Camera stabilization
• Wristed instrumentation with improved dexterity (precision with dissection, 
ease of suturing, facilitates development of surgical planes in areas riddled with 
disease)
• Avoidance of prolonged Trendelenberg
• Flexibility in instrument configuration
• Motion dampening sensors (tremor filtration)
• Depth perception due to 3D camera (less blood loss, reduced transfusions, 
reduced complications)
• May facilitate MIS for morbidly obese
• Lower conversion rate to open surgery
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